As of the end of August 2021, the first-half reports of IVD-related listed companies have basically been released. According to CACLP's financial report data of 48 IVD listed companies and 16 IVD-related listed companies, 64 companies have achieved steady growth in the first half of 2021, and more than 70% of companies have shown positive growth in net profits.
Among them, Fosun Pharma（600196. SH）'s first-half sales was 16.95 billion yuan, ranking first. According to statistics from the first-half report in IVD sales category, Mindray (300760. SZ)’s IVD products sales ranked first with 3.9671-billion-yuan, accounting for 31% of the total sales (12.78 billion yuan) in the first half of the year. This is due to domestic and part The amount of routine testing reagents in the international region has been restored. Mindray continued to increase its investment in overseas markets in the first half of this year, with a total of more than 400 new high-end customers, including 100 in Europe and more than 300 in emerging market countries, further establishing Mindray's reliable and high-quality global brand image.
At the same time, in the first half of 2021, the net profit of Hotgen (688068. SH) increased by 74263.59% year-on-year to 1.453 billion yuan; sales increased by 3904.13% year-on-year to 3.6 billion yuan, mainly due to the rapid sales of COVID-19 antigen rapid detection kit in Europe. In addition, Oriental Gene (688298. SH) also has outstanding performance in overseas markets, ranking first among 48 listed companies with sales of 6.382 billion yuan in the first half of 2021. Moreover, the net profit of Tellgen (300642. SZ) and BSBE（300406. SZ） will achieve a year-on-year growth of over 500%.
According to statistics, in terms of R&D investment, a total of 15 companies’R&D investment accounted for more than 10% of their sales. Among them, Rightongene (688217.SH) ranked first with 24.10% in R&D investment. From the year-on-year growth of R&D, Thalys (603716.SH)'s performance is very conspicuous, reaching 419.89%. More and more IVD companies focus on technology and technological innovation, to continue to increase their investment in research and development, and motivate themselves to maintain the scientific, reasonable and sustainable development of the companies.
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.